Table A1.

Nanomedicines in the IMPDs.

Code	Description	Nanomedicine-Related Term	Analytical Method Confirming Nanoscale Dimension	Pharmaceutical Form	Study Phase	Therapeutic Area	Active Substance of Chemical Origin?	Active Substance of Biological/Biotechnological Origin?	Gene Therapy Medicinal Product?
N1	Serotype 5 adenovirus vector	Nanocarrier	Yes	Concentrate for solution for injection	I/II	Cancer	No	No	Yes
N2	Adeno-associated virus serotype 8 gene therapy vector	Nanocarrier	Yes	Solution for injection	I/II	Blood and lymphatic diseases	No	No	Yes
N3	Monoclonal antibody conjugated to a DNA alkylating agent through a linker	Antibody–drug conjugate (ADC)	No	Powder for solution for infusion	I	Cancer	No	Yes	No
N4	Adeno-associated virus serotype 9 vector	Nanocarrier	No	Solution for infusion	III	Nervous system diseases	No	Yes	Yes
N5	Adeno-associated virus serotype 8 gene therapy vector	Nanocarrier	No	Concentrate for solution for infusion	I/II	Nutritional and metabolic diseases	No	No	Yes
N6	Recombinant adeno-associated viral vector	Nanocarrier	Yes	Concentrate for solution for infusion	II	Congenital, hereditary and neonatal diseases and abnormalities	No	No	Yes
N7	PEGylated enzyme	Polymer therapeutic	No	Solution for injection	III	Genetic phenomena	No	Yes	No
N8	Monoclonal antibody conjugated to a prodrug through a linker	Antibody–drug conjugate (ADC)	Yes	Powder for solution for infusion	III	Cancer	Yes	Yes	No
N9	Monoclonal antibody conjugated to an antimitotic agent through a linker	Antibody–drug conjugate (ADC)	No	Powder for solution for infusion	III	Cancer	No	Yes	Yes
N10	Recombinant adeno-associated virus vector serotype 2	Nanocarrier	No	Suspension for injection	III	Eye diseases	No	No	Yes
N11	Monoclonal antibody conjugated to an antimitotic agent through a linker	Antibody–drug conjugate (ADC)	No	Powder for solution for injection	I	Cancer	No	Yes	No
N12	Monoclonal antibody conjugated to a cytotoxic agent through a linker	Antibody–drug conjugate (ADC)	No	Powder for solution for infusion	I	Cancer	No	Yes	No
N13	Vaccinia virus vector	Nanocarrier	No	Solution for injection	I/II	Virus diseases	No	Yes	Yes
N14	Adeno-associated virus serotype 5 vector	Nanocarrier	Yes	Solution for infusion	III	Blood and lymphatic diseases	No	No	Yes
N15	Monoclonal antibody conjugated to a cytotoxic agent through a linker	Antibody–drug conjugate (ADC)	No	Powder for solution for infusion	III	Cancer	Yes	Yes	No
N16	Trivalent Nanobody	Nanobody	No	Nebulizer solution	II	Virus diseases	No	Yes	No
N17	Pegylated peptide	Polymer therapeutic	No	Solution for injection	II	Blood and lymphatic diseases	Yes	No	No
N18	Glycopegylated recombinant protein	Polymer therapeutic	No	Powder and solvent for solution for injection	III	Congenital, hereditary and neonatal diseases and abnormalities	No	Yes	No
N19	Monoclonal antibody conjugated to a cytotoxic agent through a linker	Antibody–drug conjugate (ADC)	No	Solution for infusion	II	Cancer	No	Yes	No
N20	Pegylated oligonucleotide	Polymer therapeutic	No	Solution for injection	II	Eye diseases	Yes	No	No
N21	Monoclonal antibody conjugated to an antimitotic agent through a linker	Antibody–drug conjugate (ADC)	No	Solution for infusion	II	Cancer	Yes	Yes	No
N22	Monoclonal antibody conjugated to an antimitotic agent through a linker	Antibody–drug conjugate (ADC)	No	Powder for solution for infusion	II	Cancer	No	Yes	No